Cargando…
Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis
OBJECTIVE: Given that the coronavirus disease 2019 (COVID-19) mainly spreads through the respiratory system and is associated with severe pulmonary complications, lung cancer patients may have worse outcomes than those with other tumors. There is no confirmed evidence about the mortality comparison...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier B.V.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098047/ https://www.ncbi.nlm.nih.gov/pubmed/33985850 http://dx.doi.org/10.1016/j.lungcan.2021.05.002 |
_version_ | 1783688432737845248 |
---|---|
author | Lei, Haike Yang, Yue Zhou, Wei Zhang, Mengyang Shen, Yang Tao, Dan Wang, Lulu Lei, Qianqian Wang, Ying Wu, Yongzhong |
author_facet | Lei, Haike Yang, Yue Zhou, Wei Zhang, Mengyang Shen, Yang Tao, Dan Wang, Lulu Lei, Qianqian Wang, Ying Wu, Yongzhong |
author_sort | Lei, Haike |
collection | PubMed |
description | OBJECTIVE: Given that the coronavirus disease 2019 (COVID-19) mainly spreads through the respiratory system and is associated with severe pulmonary complications, lung cancer patients may have worse outcomes than those with other tumors. There is no confirmed evidence about the mortality comparison between COVID-19 patients with lung cancer and other tumors. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate of COVID-19 patients with lung cancer and other tumors. MATERIALS AND METHODS: Our study systemically included and reviewed 13 studies on the characteristics of COVID-19 patients with lung cancer published up to November 1, 2020. The primary endpoint was all-cause mortality. We also compared the all-cause mortality rates in China and other regions as a secondary endpoint. The mortality rate was assessed with a fixed-effects model, which was used to derive the pooled mortality and 95 % confidence interval (CI). RESULTS: Thirteen studies from different countries, involving 1,229 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 343 deaths were recorded in this population: 86 for lung cancers and 257 for other tumors. The mortality rate varies from 18 % to 60 % for patients with lung cancer and COVID-19 and 10%–41% for other tumor patients with COVID-19. The overall meta-analysis did not show a significant mortality difference for the lung cancer and other tumor subgroups (OR = 1.47, 95 %CI = 0.98–2.20, p = 0.06, I(2) = 23 %). Nevertheless, in regions other than China, the pooled mortality of lung cancer patients with COVID-19 was 42 %, which was significantly higher than that of other tumors (24 %) (OR = 2.73, 95 % CI = 1.54–4.86, p = 0.0006, I(2) = 16 %). CONCLUSION: Appropriate and aggressive preventive measures should be implemented to reduce the risk of COVID-19 in patients with cancer and optimally manage those who contract the infection. |
format | Online Article Text |
id | pubmed-8098047 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | The Authors. Published by Elsevier B.V. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80980472021-05-05 Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis Lei, Haike Yang, Yue Zhou, Wei Zhang, Mengyang Shen, Yang Tao, Dan Wang, Lulu Lei, Qianqian Wang, Ying Wu, Yongzhong Lung Cancer Article OBJECTIVE: Given that the coronavirus disease 2019 (COVID-19) mainly spreads through the respiratory system and is associated with severe pulmonary complications, lung cancer patients may have worse outcomes than those with other tumors. There is no confirmed evidence about the mortality comparison between COVID-19 patients with lung cancer and other tumors. We performed a systematic review and pooled analysis to provide precise estimates of the mortality rate of COVID-19 patients with lung cancer and other tumors. MATERIALS AND METHODS: Our study systemically included and reviewed 13 studies on the characteristics of COVID-19 patients with lung cancer published up to November 1, 2020. The primary endpoint was all-cause mortality. We also compared the all-cause mortality rates in China and other regions as a secondary endpoint. The mortality rate was assessed with a fixed-effects model, which was used to derive the pooled mortality and 95 % confidence interval (CI). RESULTS: Thirteen studies from different countries, involving 1,229 patients with both COVID-19 and cancer, were selected for the pooled analysis. A total of 343 deaths were recorded in this population: 86 for lung cancers and 257 for other tumors. The mortality rate varies from 18 % to 60 % for patients with lung cancer and COVID-19 and 10%–41% for other tumor patients with COVID-19. The overall meta-analysis did not show a significant mortality difference for the lung cancer and other tumor subgroups (OR = 1.47, 95 %CI = 0.98–2.20, p = 0.06, I(2) = 23 %). Nevertheless, in regions other than China, the pooled mortality of lung cancer patients with COVID-19 was 42 %, which was significantly higher than that of other tumors (24 %) (OR = 2.73, 95 % CI = 1.54–4.86, p = 0.0006, I(2) = 16 %). CONCLUSION: Appropriate and aggressive preventive measures should be implemented to reduce the risk of COVID-19 in patients with cancer and optimally manage those who contract the infection. The Authors. Published by Elsevier B.V. 2021-07 2021-05-05 /pmc/articles/PMC8098047/ /pubmed/33985850 http://dx.doi.org/10.1016/j.lungcan.2021.05.002 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Lei, Haike Yang, Yue Zhou, Wei Zhang, Mengyang Shen, Yang Tao, Dan Wang, Lulu Lei, Qianqian Wang, Ying Wu, Yongzhong Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis |
title | Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis |
title_full | Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis |
title_fullStr | Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis |
title_full_unstemmed | Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis |
title_short | Higher mortality in lung cancer patients with COVID-19? A systematic review and meta-analysis |
title_sort | higher mortality in lung cancer patients with covid-19? a systematic review and meta-analysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8098047/ https://www.ncbi.nlm.nih.gov/pubmed/33985850 http://dx.doi.org/10.1016/j.lungcan.2021.05.002 |
work_keys_str_mv | AT leihaike highermortalityinlungcancerpatientswithcovid19asystematicreviewandmetaanalysis AT yangyue highermortalityinlungcancerpatientswithcovid19asystematicreviewandmetaanalysis AT zhouwei highermortalityinlungcancerpatientswithcovid19asystematicreviewandmetaanalysis AT zhangmengyang highermortalityinlungcancerpatientswithcovid19asystematicreviewandmetaanalysis AT shenyang highermortalityinlungcancerpatientswithcovid19asystematicreviewandmetaanalysis AT taodan highermortalityinlungcancerpatientswithcovid19asystematicreviewandmetaanalysis AT wanglulu highermortalityinlungcancerpatientswithcovid19asystematicreviewandmetaanalysis AT leiqianqian highermortalityinlungcancerpatientswithcovid19asystematicreviewandmetaanalysis AT wangying highermortalityinlungcancerpatientswithcovid19asystematicreviewandmetaanalysis AT wuyongzhong highermortalityinlungcancerpatientswithcovid19asystematicreviewandmetaanalysis |